Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025

Description

Anti-vascular endothelial growth factor (VEGF) therapeutics constitute a class of medications designed to impede the growth of blood vessels, particularly prevalent in the treatment of ophthalmic conditions. These drugs function by inhibiting vascular endothelial growth factors and find widespread application in the therapeutic intervention of various tumors and age-related macular degeneration.

The primary products within the category of anti-vascular endothelial growth factor therapeutics include Eylea, Lucentis, and Beovu. Eylea is a medication specifically indicated for the treatment of certain eye conditions, such as macular degeneration and diabetic retinopathy. Serving as an anti-VEGF therapeutic agent, Eylea effectively hinders the abnormal growth of blood vessels in the eye, particularly associated with retinal diseases. The utilization of anti-vascular endothelial growth factor therapeutics extends to the treatment of macular edema, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration. These therapeutics are commonly employed by hospitals, clinics, oncology centers, and other healthcare facilities in addressing a range of ophthalmic disorders.

The anti-vascular endothelial growth factor therapeutics market research report is one of a series of new reports from The Business Research Company that provides anti-vascular endothelial growth factor therapeutics market statistics, including anti-vascular endothelial growth factor therapeutics industry global market size, regional shares, competitors with a anti-vascular endothelial growth factor therapeutics market share, detailed anti-vascular endothelial growth factor therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the anti-vascular endothelial growth factor therapeutics industry. This anti-vascular endothelial growth factor therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-vascular endothelial growth factor therapeutics market size has grown marginally in recent years. It will grow from$12.2 billion in 2024 to $12.31 billion in 2025 at a compound annual growth rate (CAGR) of 1.0%. The growth in the historic period can be attributed to rise in age-related macular degeneration, increased incidence of diabetic retinopathy, advancements in retinal disease diagnosis, clinical success and efficacy, shift to outpatient treatment

The anti-vascular endothelial growth factor therapeutics market size is expected to see steady growth in the next few years. It will grow to $13.49 billion in 2029 at a compound annual growth rate (CAGR) of 2.3%. The growth in the forecast period can be attributed to aging population and ocular diseases, expanding applications in retinal disorders, development of next-generation therapeutics, increasing emphasis on early intervention, global health initiatives and access to treatment. Major trends in the forecast period include increasing utilization in cancer treatment, focus on combination therapies in ophthalmology, exploration of biosimilar versions, research on resistance mechanisms, integration with imaging technologies.

The rise in the incidence of ophthalmic diseases is anticipated to drive the expansion of the anti-vascular endothelial growth factor therapeutics market. Ophthalmic disease prevalence signifies the occurrence of specific eye conditions or disorders within a given population. Anti-vascular endothelial growth factor (VEGF) therapeutics play a pivotal role in combating prevalent eye ailments such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. As of October 2022, the World Health Organization reported global vision impairment affecting approximately 2.2 billion people, with specific conditions impacting 1 billion individuals, including 8 million with age-related macular degeneration and approximately 3.9 million experiencing diabetic retinopathy. This prevalence underscores the driving force behind the growth of the anti-vascular endothelial growth factor therapeutics market.

Increasing investment in healthcare infrastructure is anticipated to drive the growth of the anti-vascular endothelial growth factor (VEGF) therapeutics market in the future. This expenditure encompasses the financial resources allocated to developing, maintaining, and enhancing healthcare facilities and assets, including hospitals, clinics, medical equipment, and information systems. Such investments play a vital role in the anti-VEGF therapeutics market by improving treatment accessibility, facilitating the adoption of new technologies, raising awareness and promoting early detection, and encouraging public-private partnerships in research and development. For example, in May 2024, the Office for National Statistics, a UK-based government agency, reported that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a mere 0.9% growth in 2022. Thus, the rising investment in healthcare infrastructure is propelling the growth of the anti-VEGF therapeutics market.

Advancements in therapeutic approaches represent a prominent trend driving growth within the anti-vascular endothelial growth factor therapeutics market. Companies active in this domain are embracing cutting-edge therapeutic methodologies to fortify their market presence. For instance, in May 2022, Ashvattha Therapeutics Inc., a US-based biopharmaceutical firm, disclosed phase 1 safety data for healthy subjects concerning their subcutaneous anti-VEGF wet AMD and DME candidates, namely D-4517.2 therapy. D-4517.2 is an innovative therapy designed to target unaddressed needs in DME conditions. Notably, this therapy is designed for self-administration through an autoinjector, allowing patients the convenience of self-administering the medication once monthly from the comfort of their homes.

Major players within the anti-vascular endothelial growth factor therapeutics sphere are strategically aligning through partnerships to propel the development and commercialization of VEGF inhibitors, thereby optimizing market gains. Such collaborations play a pivotal role in steering research and development, accessing novel technologies and candidates, expanding market penetration, and facilitating the commercial launch of VEGF inhibitors. For example, in June 2022, Biogen Inc., a US-based biotech enterprise, in collaboration with Samsung Bioepis, a South Korea-based biopharmaceutical company, introduced BYOOVIZ (ranibizumab-nuna) in the United States. BYOOVIZ stands as the premier FDA-endorsed ophthalmology biosimilar, specifically tailored for treating neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, and myopic choroidal neovascularization. Functioning as a vascular endothelial growth factor (VEGF) inhibitor, BYOOVIZ marks the inaugural biosimilar launch in the U.S. within the Biogen and Samsung Bioepis partnership. Under this collaboration, Samsung Bioepis is accountable for development, regulatory processes, and product manufacture, while Biogen shoulders the responsibility for commercialization.

In August 2022, Coherus BioSciences Inc., a US-based commercial-stage biopharmaceutical company, acquired the commercialization rights to FYB203 from Klinge Biopharma GmbH for an undisclosed amount. This acquisition significantly enhances Coherus's portfolio of ophthalmology products, particularly within the anti-vascular endothelial growth factor (anti-VEGF) segment. Klinge Biopharma GmbH, based in Germany, specializes in pharmaceutical manufacturing, and this deal allows Coherus to strengthen its position in the growing market for therapies targeting conditions such as age-related macular degeneration and diabetic retinopathy, which are treated using anti-VEGF medications.

Major companies operating in the anti-vascular endothelial growth factor therapeutics market include F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc, Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.

North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024. Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anti-vascular endothelial growth factor therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The anti-vascular endothelial growth factor therapeutics market consists of revenues earned by entities by providing lapatinib (tykerb), sorafenib (nexavar), sunitinib (sutent), axitinib, and pazopanib. The market value includes the value of related goods sold by the service provider or included within the service offering. The anti-vascular endothelial growth factor therapeutics market also includes sales of drugs, injectables, and therapy-related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-vascular endothelial growth factor therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-vascular endothelial growth factor therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-vascular endothelial growth factor therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product: Eylea; Lucentis; Beovu
2) By Disease: Macular Edema; Diabetic Retinopathy; Retinal Vein Occlusion; Age-related Macular Degeneration
3) By End Users: Hospitals; Clinics; Oncology Centers; Other End Users
Subsegments:
1) By Eylea: Indications; Dosage Forms
2) By Lucentis: Indications; Dosage Forms
3) By Beovu: Indications; Dosage Forms
Companies Mentioned: F. Hoffmann-La Roche AG; Biogen Inc.; Pfizer Inc.; Coherus BioSciences Inc.; Eli Lilly and Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r23927

1. Executive Summary

2. Anti-Vascular Endothelial Growth Factor Therapeutics Market Characteristics

3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Trends And Strategies

4. Anti-Vascular Endothelial Growth Factor Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Anti-Vascular Endothelial Growth Factor Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Anti-Vascular Endothelial Growth Factor Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Growth Rate Analysis
5.4. Global Anti-Vascular Endothelial Growth Factor Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Anti-Vascular Endothelial Growth Factor Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Anti-Vascular Endothelial Growth Factor Therapeutics Total Addressable Market (TAM)

6. Anti-Vascular Endothelial Growth Factor Therapeutics Market Segmentation

6.1. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Eylea
Lucentis
Beovu
6.2. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-related Macular Degeneration
6.3. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Oncology Centers
Other End Users
6.4. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Sub-Segmentation Of Eylea, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Indications
Dosage Forms
6.5. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Sub-Segmentation Of Lucentis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Indications
Dosage Forms
6.6. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Sub-Segmentation Of Beovu, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Indications
Dosage Forms

7. Anti-Vascular Endothelial Growth Factor Therapeutics Market Regional And Country Analysis

7.1. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market

8.1. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anti-Vascular Endothelial Growth Factor Therapeutics Market

9.1. China Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
9.2. China Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anti-Vascular Endothelial Growth Factor Therapeutics Market

10.1. India Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market

11.1. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
11.2. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market

12.1. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anti-Vascular Endothelial Growth Factor Therapeutics Market

13.1. Indonesia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market

14.1. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
14.2. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market

15.1. Western Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
15.2. Western Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anti-Vascular Endothelial Growth Factor Therapeutics Market

16.1. UK Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market

17.1. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anti-Vascular Endothelial Growth Factor Therapeutics Market

18.1. France Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market

19.1. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market

20.1. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market

21.1. Eastern Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
21.2. Eastern Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market

22.1. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market

23.1. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
23.2. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anti-Vascular Endothelial Growth Factor Therapeutics Market

24.1. USA Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
24.2. USA Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market

25.1. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
25.2. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market

26.1. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
26.2. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market

27.1. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anti-Vascular Endothelial Growth Factor Therapeutics Market

28.1. Middle East Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
28.2. Middle East Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market

29.1. Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
29.2. Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anti-Vascular Endothelial Growth Factor Therapeutics Market Competitive Landscape And Company Profiles

30.1. Anti-Vascular Endothelial Growth Factor Therapeutics Market Competitive Landscape
30.2. Anti-Vascular Endothelial Growth Factor Therapeutics Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Coherus BioSciences Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Anti-Vascular Endothelial Growth Factor Therapeutics Market Other Major And Innovative Companies

31.1. Bausch Health Companies Inc.
31.2. Viatris Inc.
31.3. Xbrane Biopharma AB
31.4. Bayer AG
31.5. Regeneron Pharmaceuticals Inc.
31.6. Genentech Inc
31.7. Allergan Inc.
31.8. Novartis AG
31.9. kyowa Kirin Co. Ltd.
31.10. Amgen Inc.
31.11. AstraZeneca plc
31.12. Merck & Co. Inc.
31.13. Johnson & Johnson Private Limited
31.14. Sanofi S.A.
31.15. AbbVie Inc.

32. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-Vascular Endothelial Growth Factor Therapeutics Market

34. Recent Developments In The Anti-Vascular Endothelial Growth Factor Therapeutics Market

35. Anti-Vascular Endothelial Growth Factor Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Anti-Vascular Endothelial Growth Factor Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Anti-Vascular Endothelial Growth Factor Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Anti-Vascular Endothelial Growth Factor Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer